ENIGMA GENETICS
Biological Identity & Consent Infrastructure
Building A Baseline For the Future.
Digital identity is failing. Biology is the hard fork.
The Collapse
In the age of generative AI, everything digital—voice, video, biometrics, and code—is becoming synthetic and forgeable at scale. Digital trust is collapsing faster than regulation can respond.
The Thesis
Biology is the only non-synthetic root of identity left.
The Solution
Enigma Genetics is building the sovereign infrastructure for biological identity and consent—the anchor layer between biological truth and digital systems.
Rare Disease: Where biology already has buyers
High Stakes
Rare and Mendelian disease data is the most valuable per-byte information in healthcare. Each delayed clinical trial can cost pharma $20M+ per month in lost exclusivity and downstream revenue.
The Gap
Today's data is fragmented, unverified, and often non-consensual—creating regulatory risk, identity fraud, and scientific uncertainty.
The Market Reality
Pharma and clinics already pay premiums for verified, legally usable cohorts—but no trusted identity standard exists.
The Wedge: We solve the verification and consent crisis for the most desperate, highest-paying market first.
CypherGlyph™ — The Biological Proof-of-Personhood
CypherGlyph™
Transforms biological state into a non-reversible cryptographic proof—privacy-preserving and non-diagnostic.
1
Initial Biological Capture (One-Time Event)
User provides biological sample → Sequencing by certified lab → Raw data never exposed
Output: Verified biological dataset
2
Identity Binding & CypherGlyph™ Issuance
Biological data cryptographically bound to unique identity → CypherGlyph™ generated as biological root-of-trust
Output: Portable, non-replayable biological identity token
3
Secure Storage in GeneVault™
Encrypted storage of all biological, clinical, and analytic data → No access without live consent
Output: Sovereign, encrypted biological data vault
4
Live Consent via Unifacator™
Access request triggers biometric verification → User grants scope-limited, time-bound consent
Output: Consent-as-code authorization
5
Controlled Data Hydration
Only approved data fields released → Zero-knowledge proofs where possible
Output: Minimal, purpose-bound data access
6
Audit & Compliance Logging (SignaChain™)
Every scan, consent, and data release immutably logged → HIPAA/GDPR/eIDAS-aligned
Output: Tamper-proof compliance ledger
7
Analytics & Reuse (OmniMind™)
Longitudinal epigenetic drift modeling → Cohort analytics, clinical insights
Output: Compounding value per verified identity
Result: Zero identity fraud • Audit-ready consent • Full ownership and economic participation
Architecture, not discovery
Technical De-Risking
No scientific breakthrough required. We assemble mature genomics technologies with battle-tested cryptography.
The George Church Standard
This aligns with George Church's long-standing position: biology must be secure, accessible, and sovereign to be useful at scale.
The Shift
Risk moves from science uncertainty to execution quality.
Impossible to copy by design
Defensibility in this space isn't just about technology—it's about creating structural advantages that compound over time. Our moat deepens with every clinic partnership and every patient who chooses sovereignty.
Patent Strategy
Foundational IP covering CypherGlyph™ encryption and biological-to-digital identity linking.
Consent-as-Code
Consent travels with the data. Rogue data becomes cryptographically unusable.
Data Gravity
Each verified ID increases switching costs. Once embedded, displacement becomes economically irrational.
Regulatory Moat
GDPR/HIPAA "Right to be Forgotten" enforced at the protocol level—not a policy patch.
High-margin revenue from day one
Clinics (B2B SaaS)
$30–$50 PMPM for identity and consent infrastructure.
Pharma (B2B Contracts)
$250k–$2M+ per cohort engagement. Multi-year contracts embedded in trial workflows.
Economics
70–90% gross margins. We provide infrastructure—not lab services.
Infrastructure first. Disease-funded. Reversion enabled.
Phase 0: Foundation
Biological identity, consent-as-code, longitudinal baselines.
Phase 1: Mendelian Disease (Revenue Engine)
High-urgency cohorts fund infrastructure refinement and scale.
Phase 2: Longitudinal Mapping
Time-series biological and epigenetic state tracking.
Phase 3: Reversion & Longevity
Ethical, targeted reversion enabled by trusted longitudinal data.
Go-to-Market Economics
$15-25K
CAC (Customer Acquisition Cost)
Per clinic (sales cycle, onboarding, integration)
$180K+
LTV (Lifetime Value)
Per clinic over 3 years (PMPM recurring + cohort fees)
7-12x
LTV:CAC Ratio
6-9
Payback Period (Months)
The unified architecture allows for near-zero marginal cost as we expand into each new market vertical. We build the rails once, then monetize access across multiple high-value use cases.
Key Principle: We don't start with reversion. We earn our way to it.
Operating Leverage & Unit Economics
One-Time Biological Verification
Initial identity verification (sequencing + binding): $180 / user
Non-recurring per identity
Ongoing Marginal Cost (Post-Verification)
Storage, compute, audit, compliance: ~$25 / user / year
Revenue Per Verified Identity (5-Year View)
  • Consumer SaaS: $1,800
  • Clinical reuse: $900
  • Research / ZK queries: $450
  • Total LTV: $3,150
Gross Margins
  • Year-1 gross margin: ~93%
  • Lifetime gross margin: ~90%
  • LTV : Cost = 10.3×
Why This Scales
  • Verification is a one-time event
  • Each additional clinic or cohort reuses the same verified identity
  • Revenue compounds while marginal cost remains software-level
Software economics applied to biological identity.
Start Narrow. Become Unavoidable.
Vertical Expansion
One Mendelian disease → 7,000+ rare diseases.
Horizontal Expansion
Clinics → national health systems → global biobanks.
End State
The default identity layer for the bio-economy.
"Land narrow, expand inevitable. Start where the pain is sharpest. End where you're indispensable."
A Focused Beachhead into a Massive Future
Bottom-Up Market Calculation
Phase 1 SAM (Rare Disease):
  • 7,000+ rare diseases × ~200 specialized clinics per disease
  • Average clinic value: $30-50k/year (PMPM model)
  • Pharma cohort contracts: $250k-$2M per engagement
  • Addressable: $4.8B+
Phase 1 SAM
$4.8B+ rare disease pharma & research infrastructure.
Phase 2 TAM
$100B+ Identity & Access Management as AI forces biological verification.
Strategic Focus: High-signal, high-margin data—not consumer genetics.
Team (Founding)
Ken Clark — Founder & CEO
Combat veteran and operations engineer. Built mission-critical systems under hard constraints.
Core expertise:
System architecture & data pipelines
Identity, consent, governance
Manufacturing automation & infrastructure
Builds what must exist first, not what's fashionable.
Scientific Validation
Dr. George Church
Harvard Medical School
Pioneer: Genomics, CRISPR, Synthetic Biology
Validated thesis as scientifically feasible today via systems integration.
Strategic Advisors & Partners
[Domain experts in genomics, identity infrastructure, and regulated markets]
Traction & Milestones
Technical Validation
  • CypherGlyph™ architecture validated and documented
  • Cryptographic proof-of-concept: Identity binding tested with 100+ synthetic samples
  • Dr. George Church scientific validation: Confirmed feasible via systems integration
Market Validation
  • 12+ clinic and domain expert conversations completed
  • 3 rare disease cohorts identified for pilot (Duchenne MD, Cystic Fibrosis, Rett Syndrome)
  • 8 active investor conversations; 2 term sheet discussions
Product Development
  • Identity verification pipeline: Core modules built, testing phase
  • Consent-as-code framework: Policy engine 60% complete
  • Sequencing partnerships: 2 LOIs signed, 1 pilot agreement in negotiation
Next 12 Months
  • Q1: First paid pilot ($50k contract)
  • Q2: CypherGlyph™ beta launch with 3 clinic partners
  • Q3: 25–50 patient cohort verification complete
  • Q4: $500k ARR run rate, enterprise pricing finalized
Execution-driven milestones. No scientific breakthroughs required.
The Ask:
Raising: $2.5M Seed Round
Use of Funds
40%
Product Development
CypherGlyph™ beta → production-grade platform. Identity verification, consent-as-code, and audit infrastructure. Security hardening and scalability.
25%
Go-to-Market
Launch first 3–5 clinic partnerships. Clinical onboarding, pilot execution, and conversion to paid contracts. Early enterprise identity validation use cases.
20%
Team
Key technical hires (platform, security, data). Founding-level partner(s) with real ownership and authority.
15%
Operations & Compliance
Infrastructure, regulatory readiness, and data governance. Legal, privacy, and security compliance required for clinical and enterprise adoption.
12-Month Milestones:
  • ✓ 3–5 clinic partnerships live
  • ✓ 500+ verified CypherGlyph™ identities
  • ✓ First pharma cohort contract ($250k+)
  • ✓ Founding team complete
18-Month Vision:
• 10+ clinic network
• 2,000+ verified identities
• $1M+ ARR from clinics and identity services
• Multiple pharma contracts
• Series A positioned
Commitments to Date:
• $750k committed from strategic angels and domain experts
• Active discussions with institutional investors
• Clinical and domain validation in progress
• Advisory validation from leaders in genomics and identity infrastructure
Seeking: $2.5M to close the round
This round closes the gap between validation and scale.
Infrastructure doesn't compete. It becomes mandatory.
Digital identity is broken.
Biology is the only fix.
Enigma is the bridge
Between biological truth and digital trust.
"We're not monetizing DNA. We're monetizing trust."
The question isn't whether this infrastructure will exist. The question is who builds it first—and captures the network effects.
Contact
Ken Clark, Founder & CEO
We're assembling the team that builds the standard.